This phase I trial is evaluating a new targeted therapy in patients with advanced cancers and cancers that have spread to other parts of the body.
This trial is treating patients with advanced solid cancer (excluding some types of blood cancer).
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
First-in-human (FIH), Open-Label, Phase I (Dose Escalation) Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Eligible patients will receive intravenous ADG116 on Day 1 of each treatment cycle.
Recruiting Hospitals Read More